Abstract
The worldwide epidemic of ischemic disease urgently requires innovative treatments. Recently, therapeutic angiogenesis has emerged as a noninvasive supply-side approach, aimed at promoting neovascularization in underperfused tissues through the local delivery of angiogenic growth factors. Successful preclinical studies paved the way for the first clinical trials, with single growth factors given as recombinant proteins or genes. However, clinical results have not matched the initial promises. Our opinion is that the logic of therapeutic angiogenesis needs profound revision. Here, we introduce the concept that pleiotropic agents can stimulate the healing of all the components of ischemic tissue. We also propose prophylactic interventions to delay vascular senescence. The optimization of therapeutic angiogenesis will open unprecedented opportunities for the care of life-threatening ischemic disease.
Translated title of the contribution | Changing the logic of therapeutic angiogenesis for ischemic disease |
---|---|
Original language | English |
Pages (from-to) | 207 - 216 |
Number of pages | 10 |
Journal | Trends in Molecular Medicine |
Volume | 11 |
Issue number | 5 |
DOIs | |
Publication status | Published - May 2005 |
Keywords
- Angiogenesis Inducing Agents
- Animals
- Clinical Trials as Topic
- Humans
- Myocardial Ischemia
- Neovascularization, Pathologic
- Neovascularization, Physiologic
- Recombinant Proteins